Insider Monkey
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline
📈
AI Sentiment
Highly Positive
8/10
- Home
- ROIV
as of 01-02-2026 3:50pm EST
$21.87
+$0.17
+0.78%
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 14.1B | IPO Year: | N/A |
| Target Price: | $24.31 | AVG Volume (30 days): | 8.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.73 - $23.47 | Next Earning Date: | 02-09-2026 |
| Revenue: | $20,329,000 | Revenue Growth: | -45.13% |
| Revenue Growth (this year): | -34.21% | Revenue Growth (next year): | 741.42% |
AI-Powered ROIV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 71.34%
71.34%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
Venker Eric
Sell
President & Immunovant CEO
ROIV Dec 24, 2025
Avg Cost/Share
$22.53
Shares
75,000
Total Value
$1,689,750.00
Owned After
1,654,597
SEC Form 4
Pulik Richard
Sell
CFO
ROIV Dec 23, 2025
Avg Cost/Share
$22.42
Shares
406,731
Total Value
$9,122,307.09
Owned After
239,413
Venker Eric
Sell
President & Immunovant CEO
ROIV Dec 23, 2025
Avg Cost/Share
$22.45
Shares
200,000
Total Value
$4,490,000.00
Owned After
1,654,597
SEC Form 4
Gold Daniel Allen
Sell
Director
ROIV Dec 17, 2025
Avg Cost/Share
$23.08
Shares
777,332
Total Value
$17,935,594.88
Owned After
16,353,113
MANCHESTER KEITH S
Sell
Director
ROIV Dec 17, 2025
Avg Cost/Share
$23.08
Shares
777,332
Total Value
$17,935,594.88
Owned After
16,353,113
QVT Financial LP
Sell
Other
ROIV Dec 17, 2025
Avg Cost/Share
$23.08
Shares
777,332
Total Value
$17,935,594.88
Owned After
16,353,113
Gold Daniel Allen
Sell
Director
ROIV Dec 16, 2025
Avg Cost/Share
$23.01
Shares
917,282
Total Value
$21,129,618.56
Owned After
16,353,113
MANCHESTER KEITH S
Sell
Director
ROIV Dec 16, 2025
Avg Cost/Share
$23.01
Shares
917,282
Total Value
$21,129,618.56
Owned After
16,353,113
QVT Financial LP
Sell
Other
ROIV Dec 16, 2025
Avg Cost/Share
$23.01
Shares
917,282
Total Value
$21,129,618.56
Owned After
16,353,113
Gline Matthew
Sell
CEO
ROIV Dec 15, 2025
Avg Cost/Share
$21.68
Shares
1,740,000
Total Value
$37,723,200.00
Owned After
17,290,820
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & Immunovant CEO | Dec 24, 2025 | Sell | $22.53 | 75,000 | $1,689,750.00 | 1,654,597 | |
| Pulik Richard | ROIV | CFO | Dec 23, 2025 | Sell | $22.42 | 406,731 | $9,122,307.09 | 239,413 | |
| Venker Eric | ROIV | President & Immunovant CEO | Dec 23, 2025 | Sell | $22.45 | 200,000 | $4,490,000.00 | 1,654,597 | |
| Gold Daniel Allen | ROIV | Director | Dec 17, 2025 | Sell | $23.08 | 777,332 | $17,935,594.88 | 16,353,113 | |
| MANCHESTER KEITH S | ROIV | Director | Dec 17, 2025 | Sell | $23.08 | 777,332 | $17,935,594.88 | 16,353,113 | |
| QVT Financial LP | ROIV | Other | Dec 17, 2025 | Sell | $23.08 | 777,332 | $17,935,594.88 | 16,353,113 | |
| Gold Daniel Allen | ROIV | Director | Dec 16, 2025 | Sell | $23.01 | 917,282 | $21,129,618.56 | 16,353,113 | |
| MANCHESTER KEITH S | ROIV | Director | Dec 16, 2025 | Sell | $23.01 | 917,282 | $21,129,618.56 | 16,353,113 | |
| QVT Financial LP | ROIV | Other | Dec 16, 2025 | Sell | $23.01 | 917,282 | $21,129,618.56 | 16,353,113 | |
| Gline Matthew | ROIV | CEO | Dec 15, 2025 | Sell | $21.68 | 1,740,000 | $37,723,200.00 | 17,290,820 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
MT Newswires
Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Compare ROIV vs Leading Stocks
See how ROIV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.